Toronto Sunnybrook Regional Cancer Centre

Summary

Toronto Sunnybrook Regional Cancer Centre is a medical facility located in TORONTO, Ontario. This center is recognized for care of Breast Cancer, Prostate Cancer, Lung Cancer, Brain Tumor, Lymphoma and other specialties. Toronto Sunnybrook Regional Cancer Centre is involved with conducting 250 clinical trials across 214 conditions. There are 29 research doctors associated with this hospital, such as Paul Karanicolas, MD, PhD, Andrew Loblaw, MD, Helen MacKay, MD, and Gerard Morton, MD, FRCPC.

Top PIs

Clinical Trials running at Toronto Sunnybrook Regional Cancer Centre

Skin Cancer

Breast Cancer

Prostate Cancer

Bladder Cancer

Testicular cancer

Ovarian Carcinoma

Ovarian Tumors

Testicular Carcinoma

Ovarian Choriocarcinoma

Small Cell Lung Cancer

Cemiplimab + Surgery

for Advanced Skin Cancer

This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cemiplimab has been approved for the treatment of skin cancer that has spread or that cannot be removed by surgery, but it has not been approved for the treatment of skin cancer than can be removed by surgery. Adding cemiplimab to the usual treatment of surgery with or without radiation may be more effective in treating patients with stage III/IV resectable squamous cell skin cancer than the usual treatment alone.

Recruiting

2 awards

Phase 3

7 criteria

Nivolumab + Cabozantinib

for Melanoma

This trial tests if nivolumab and cabozantinib can help patients with mucosal melanoma. Nivolumab boosts the immune system, while cabozantinib stops cancer cells from growing. The goal is to prevent the cancer from coming back or spreading. Nivolumab and cabozantinib have shown efficacy in treating various cancers, including melanoma and renal cell carcinoma.

Recruiting

0 awards

Phase 2